Skip to main content

Hemab Therapeutics Holdings, Inc 10-Q for FY2026 Q3

Hemab Therapeutics Holdings, Inc. (COAG)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Hemab Therapeutics Holdings, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Hemab Therapeutics Holdings, Inc. initiated SOLARA Phase 3 of sutacimig in November 2026. Its nine-month net loss was $74.1 million, while cash and marketable securities totaled $430.2 million as of September 30, 2026, funding operations into 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$27.3M
compared with a net loss of $17.07M a year earlier
Diluted EPS
-$0.58
compared with -$18.04 a year earlier